Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Thyroid hormone is required for hypothalamic neurons regulating cardiovascular functions
Jens Mittag, … , Anders Arner, Björn Vennström
Jens Mittag, … , Anders Arner, Björn Vennström
Published December 21, 2012
Citation Information: J Clin Invest. 2013;123(1):509-516. https://doi.org/10.1172/JCI65252.
View: Text | PDF
Research Article

Thyroid hormone is required for hypothalamic neurons regulating cardiovascular functions

  • Text
  • PDF
Abstract

Thyroid hormone is well known for its profound direct effects on cardiovascular function and metabolism. Recent evidence, however, suggests that the hormone also regulates these systems indirectly through the central nervous system. While some of the molecular mechanisms underlying the hormone’s central control of metabolism have been identified, its actions in the central cardiovascular control have remained enigmatic. Here, we describe a previously unknown population of parvalbuminergic neurons in the anterior hypothalamus that requires thyroid hormone receptor signaling for proper development. Specific stereotaxic ablation of these cells in the mouse resulted in hypertension and temperature-dependent tachycardia, indicating a role in the central autonomic control of blood pressure and heart rate. Moreover, the neurons exhibited intrinsic temperature sensitivity in patch-clamping experiments, providing a new connection between cardiovascular function and core temperature. Thus, the data identify what we believe to be a novel hypothalamic cell population potentially important for understanding hypertension and indicate developmental hypothyroidism as an epigenetic risk factor for cardiovascular disorders. Furthermore, the findings may be beneficial for treatment of the recently identified patients that have a mutation in thyroid hormone receptor α1.

Authors

Jens Mittag, David J. Lyons, Johan Sällström, Milica Vujovic, Susi Dudazy-Gralla, Amy Warner, Karin Wallis, Anneke Alkemade, Kristina Nordström, Hannah Monyer, Christian Broberger, Anders Arner, Björn Vennström

×

Figure 4

Effect of the in vivo ablation of AHA pv cells in pvCre mice.

Options: View larger image (or click on image) Download as PowerPoint
Effect of the in vivo ablation of AHA pv cells in pvCre mice.
(A) AAV co...
(A) AAV construct before and after Cre recombination. CMV, cytomegalovirus promotor; loxP, Cre recombination site; tpA, triple polyadenylation site; neoR, neomycin resistance gene; dtA, diphtheria toxin A. (B) Immunohistochemistry for EGFP at the site of the injection (indicated by asterisks) showing AAV-infected cells (scale bar: 250 μm). (C) Immunohistochemistry for pv in AAV-injected wild-type, nonablated pvCre, or AAV-injected ablated pvCre mice (the overall ablation efficiency is shown in the cell count at the bottom; ***P < 0.001 to nonablated, unpaired 2-tailed Student’s t test; the respective groups for the subsequent cardiac and metabolic analyses had cell counts of 81 ± 13 in the ablated animals vs. 142 ± 10 in the nonablated animals; n = 6, P = 0.002; scale bar: 500 μm). Asterisks indicate the site of injection. (D) Systolic, diastolic, and mean arterial blood pressure in mice with reduced numbers of pv+ cells in the AHA (black bars) and controls (white bars; *P < 0.05 for ablated vs. nonablated, unpaired 2-tailed Student’s t test). (E) Heart rates in these mice (*P < 0.05 for ablated vs. nonablated at 4°C, 2-way ANOVA). (F) Change in heart rate upon pharmacological deinnervation of the parasympathetic nervous system (PSNS) (scopolamine methyl bromide) or the sympathetic nervous system (SNS) (timolol) in mice with reduced numbers of pv+ cells in the AHA (black bars) and controls (white bars; *P < 0.05 for ablation, 2-way ANOVA). All values are mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts